These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38850724)

  • 61. The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial.
    Bureau C; Thabut D; Jezequel C; Archambeaud I; D'Alteroche L; Dharancy S; Borentain P; Oberti F; Plessier A; De Ledinghen V; Ganne-Carrié N; Carbonell N; Rousseau V; Sommet A; Péron JM; Vinel JP
    Ann Intern Med; 2021 May; 174(5):633-640. PubMed ID: 33524293
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of transjugular intrahepatic portosystemic shunt (TIPS) on quantitative liver function tests.
    Baron A; Gulberg V; Sauter G; Waggershauser T; Reiser M; Gerbes AL
    Hepatogastroenterology; 1998; 45(24):2315-21. PubMed ID: 9951915
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of transjugular intrahepatic portosystemic with endoscopic treatment plus anticoagulation for esophageal variceal bleeding and portal vein thrombosis in liver cirrhosis.
    Wu W; Zhang H; Zeng Z; Wang X; Kong D
    Scand J Gastroenterol; 2022 Dec; 57(12):1494-1502. PubMed ID: 35802771
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A model to predict early hepatic encephalopathy in patients undergoing transjugular intrahepatic portosystemic shunt.
    Li Y; He X; Pang H
    Turk J Gastroenterol; 2019 Aug; 30(8):702-707. PubMed ID: 31418414
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial).
    de Wit K; Schaapman JJ; Nevens F; Verbeek J; Coenen S; Cuperus FJC; Kramer M; Tjwa ETTL; Mostafavi N; Dijkgraaf MGW; van Delden OM; Beuers UHW; Coenraad MJ; Takkenberg RB
    BMJ Open Gastroenterol; 2020 Dec; 7(1):. PubMed ID: 33372103
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Portal anatomic variants relevant to transjugular intrahepatic portosystemic shunt.
    Saad N; Darcy M; Saad W
    Tech Vasc Interv Radiol; 2008 Dec; 11(4):203-7. PubMed ID: 19527845
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Transjugular intrahepatic portosystemic shunt treatment of variceal bleeding in an unselected patient population.
    Rosenqvist K; Sheikhi R; Nyman R; Rorsman F; Sangfelt P; Ebeling Barbier C
    Scand J Gastroenterol; 2018 Jan; 53(1):70-75. PubMed ID: 28990812
    [TBL] [Abstract][Full Text] [Related]  

  • 68. High Incidence of Hepatic Encephalopathy After Viatorr Controlled Expansion Transjugular Intrahepatic Portosystemic Shunt Creation.
    Kloster ML; Ren A; Shah KY; Alqadi MM; Bui JT; Lipnik AJ; Niemeyer MM; Ray CE; Gaba RC
    Dig Dis Sci; 2021 Nov; 66(11):4058-4062. PubMed ID: 33236314
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Outcome of Children with Transjugular Intrahepatic Portosystemic Shunt: A Meta-Analysis of Individual Patient Data.
    Deniz S; Schinner R; Monroe EJ; Horslen S; Srinivasa RN; Lv Y; Fan D; Han G; Sarma MS; Srivastava A; Poddar U; Yadav R; Hoang TPT; Lange CM; Öcal O; Ricke J; Seidensticker M; Lurz E; Di Giorgio A; D'Antiga L; Wildgruber M
    Cardiovasc Intervent Radiol; 2023 Sep; 46(9):1203-1213. PubMed ID: 37532945
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A novel endovascular adjustable polytetrafluoroethylene-covered stent for the management of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.
    Weintraub JL; Mobley DG; Weiss ME; Swanson E; Kothary N
    J Vasc Interv Radiol; 2007 Apr; 18(4):563-6. PubMed ID: 17446548
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial.
    Lv Y; Qi X; He C; Wang Z; Yin Z; Niu J; Guo W; Bai W; Zhang H; Xie H; Yao L; Wang J; Li T; Wang Q; Chen H; Liu H; Wang E; Xia D; Luo B; Li X; Yuan J; Han N; Zhu Y; Xia J; Cai H; Yang Z; Wu K; Fan D; Han G;
    Gut; 2018 Dec; 67(12):2156-2168. PubMed ID: 28970291
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Transjugular intrahepatic collateral-systemic shunt is effective for cavernous transformation of the portal vein with variceal bleeding.
    Tie J; Gou X; He C; Li K; Yuan X; Jia W; Niu J; Han N; Xu J; Zhu Y; Wang W
    Hepatol Int; 2023 Aug; 17(4):979-988. PubMed ID: 37097537
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Clinical study of transjugular intrahepatic portosystemic shunt with Viatorr stent in 43 cases].
    Zhou H; Yao X; Tang SH; Xie M; Feng ZS; Qin JP
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jan; 29(1):54-59. PubMed ID: 33541024
    [No Abstract]   [Full Text] [Related]  

  • 74. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites.
    Bureau C; Thabut D; Oberti F; Dharancy S; Carbonell N; Bouvier A; Mathurin P; Otal P; Cabarrou P; Péron JM; Vinel JP
    Gastroenterology; 2017 Jan; 152(1):157-163. PubMed ID: 27663604
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: a randomized controlled trial.
    Perarnau JM; Le Gouge A; Nicolas C; d'Alteroche L; Borentain P; Saliba F; Minello A; Anty R; Chagneau-Derrode C; Bernard PH; Abergel A; Ollivier-Hourmand I; Gournay J; Ayoub J; Gaborit C; Rusch E; Giraudeau B;
    J Hepatol; 2014 May; 60(5):962-8. PubMed ID: 24480619
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Outcomes of Transjugular Intrahepatic Portosystemic Shunt and Gastric Coronary Vein Embolization for Variceal Bleeding in Cirrhotic Portal Hypertension.
    Mukhiya G; Han X; Jiao D; Bi Y; Pokhrel G; Liu Z; Li Z; He Y
    Clin Med Res; 2023 Sep; 21(3):144-154. PubMed ID: 37985166
    [No Abstract]   [Full Text] [Related]  

  • 77. Current diagnosis and management of post-transjugular intrahepatic portosystemic shunt refractory hepatic encephalopathy.
    Pereira K; Carrion AF; Martin P; Vaheesan K; Salsamendi J; Doshi M; Yrizarry JM
    Liver Int; 2015 Dec; 35(12):2487-94. PubMed ID: 26332169
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Investigating the risk factors of hepatocellular carcinoma and survival analysis for cirrhosis after transjugular intrahepatic portosystemic shunt in treating portal hypertension.
    Wei J; Li H; Li C
    J Cancer Res Ther; 2018; 14(4):826-832. PubMed ID: 29970660
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Transjugular intrahepatic portosystemic shunt vs. small-diameter prosthetic H-graft portacaval shunt: extended follow-up of an expanded randomized prospective trial.
    Rosemurgy AS; Serafini FM; Zweibel BR; Black TJ; Kudryk BT; Nord HJ; Goode SE
    J Gastrointest Surg; 2000; 4(6):589-97. PubMed ID: 11307093
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pre-emptive transjugular intrahepatic portosystemic shunt in pediatric cystic fibrosis-related liver disease and portal hypertension: prospective long-term results.
    Hermie L; Biervliet SV; Hoorens A; Cauwenberghe LV; Robberecht E; Defreyne L
    Diagn Interv Radiol; 2024 Jan; 30(1):55-64. PubMed ID: 36994654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.